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Introduction  
INTRODUCTION 
 Many of our body surfaces are colonized with a wide variety of 
microorganisms without apparent detriment.  An infection involves the 
growth and multiplication of microorganisms that result in damage to the 
host. 
 The first line defenses are the external and internal body surfaces 
that are relatively in direct contact with the external environment. 
 Traditionally, the inner defenses have been grouped into two, 
more or less distinct functional systems.  Innate immunity refers to any 
inborn resistance that is already present the first time a pathogen is 
encountered. 
 Acquired immunity refers to resistance that is weak on first 
exposure, but that increases dramatically with subsequent exposure to 
the same specific pathogen. 
 The two arms of the immune system are humoral and cell 
mediated immunity. 
 The immune system provides the human host with the ability to 
mount a specific protective response to the presence of a 
microorganism. 
 Patients with haematological malignancies comprise a special 
group in whom all the aspects of immunity are compromised as a result 
of the underlying malignancy or due to the therapeutic interventions 
employed to manage it. 
 In many cases there are multiple factors that predispose these 
patients to infections, such as neutropenia induced by therapy or bone 
marrow involvement, hypogammaglobulinemia, T-cell dysfunction and 
mucosal damage.  In addition newer therapy has changed the spectrum 
of infection that is seen in these patients.1 
 Neutropenia resulting from cytotoxic chemotherapy is the most 
common risk factor for severe bacterial infection in haematological 
malignancies.2 
 Similarly common procedures such as venepunctures, bone 
marrow aspiration and insertion of central venous access devices, 
disrupt the integument and provide nidus for colonization.3 
 The degree of neutropenia is directly related to the incidence of 
serious bacterial and fungal infection.4 
 There is a significant increase in the incidence of serious infection 
once absolute neutrophil count (ANC) falls, below 1500 cells / mm3. 
 The duration of neutropenia also contributes significantly to the 
risk of serious infection.  The risk is significantly greater at lower 
neutrophil counts.  100% patients with ANC<100 cells/mm3 lasting           
3 weeks or more develop documented infection. 
 Some malignancies are associated with specific immune defects 
that predispose to infections with particular pathogens. 
 Patients with acute leukemia have increased risk of severe gram 
negative bacterial infections as a result of quantitative or functional 
neutropenia. 
 Patients with chronic lymphocytic leukemia and multiple myeloma 
are susceptible to invasive bacterial infections from Staphylococci and 
Streptococci. Conversely patients with lymphoma have abnormalities of 
the cellular immune system resulting in an increased risk of viral 
infection and fungal infections.4 
 Infections occur in 30-50% of these patients, most often in 
patients who have advanced disease and it remains a major problem in 
the management.5 
 The overall incidence of infection in patients who have 
chemotherapy is 0.25-0.5 episodes per patient per year and increased 
upto 1.8 episodes / year in patients who have advanced disease.6 
In patients who have acute leukemia, infection alone accounts for 
70% of deaths, haemorrhage and infection together for another 10%.7 
 Neutropenic infections are an emergency and the patients should 
be started on empirical antibiotic therapy without delay immediately 
after appropriate cultures are taken. Close monitoring of the patients is 
however essential and modifications in therapy must be made 
according to the clinical and microbiological findings. 
 The majority of the treatment failures, relapses and super 
infections are generally attributed to resistant infective organisms such 
as Methicillin resistant Staphylococcus and Pseudomonas sp. or 
disseminated fungal infections.8 
 Hence a study was undertaken to identify the organisms causing 
infections in Haematological malignancies and disorders, and their 
antibiotic susceptibility patterns and also to monitor the emergence of 
resistant strain.  This will help to modify the empirical antibiotic regimens 
if necessary. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Review of literature 
REVIEW OF LITERATURE 
 Patients with haematological malignancies and disorder comprise 
nearly 3% of all hospital admission. 
 Infection is a major cause of morbidity in patients with acute 
leukemia due to therapy induced neutropenia.9 
Haematological conditions predispensing to infection 
 Leukemia are malignant neoplasm of the haematopoitic stem 
cells, characterized by diffuse displacement of the bone marrow by 
neoplastic cells. 
 Acute leukemias are characterized by accumulation of leukemic 
blasts resulting from clonal expansion of transformed stem cells as well 
as a failure of maturation into functional end cells. 
 ALL is primary a disease of children and young adults.  It consists 
of 80% of childhood acute leukemia.10 
 AML constitute only 20% of childhood leukemia.  60% of patients 
with AML achieve complete remission with chemotherapy but only 15-
30% of these remain free from disease only for 5 years.  Therefore on a 
increasing number of patients are being treated with Allogenic Bone 
marrow transplantation.10 
 CML accounts for 15-20% of all cases of leukemia,10 a disease 
primarily of adults between ages 25-60 years with peak in fourth to fifth 
decade. 
 Lymphomas are malignant neoplasm characterised by 
proliferation of cells native to the lymphoid tissue that is lymphocytes, 
Histiocytes and their precursor and derivatives. 
 Hodgkins lymphoma is distinctive by the presence of the reed 
sternberg giant cells in addition to the presence of non-neoplastic 
inflammatory cells11. 
 Non Hodgkins lymphoma – In the majority of them T cells reveal a 
characteristic chromosomal translocation.11 
 Approximately 50% of lymphomas are associated with a history of 
immunological disorder. 
 Haematological disorder includes disorders due to bone marrow 
dysfunction or disease of various cells in the blood like RBC, WBC, 
platelets leading to their lowered counts or their dysfunction. 
 In bone marrow failure pancytopenia results from deficient 
haematopoises as distinguished from blood count depression due to 
peripheral destruction of red cells, platelets and granulocytes. 
 
Factors predisposing to infection in Haematological condition 
 Common host defense impairement in Acute leukemia are 
neutropenia / neutrophil dysfunction altered mucosal and skin integrity 
thrombocytopenia (causing poor wound healing) altered cellular and 
humoral immunity (treatment related)12 
 During antineoplastic treatment, cytotoxic agents are frequently 
administered in combination with other immunosuppressive therapies, 
such as corticosteroids and radiation therapy.  Several of the cytotoxic 
agents notably methotrexate, cyclophosphamide, 6-mercaptopurine, 
and azathioprine, impair cell-mediated immunity.12  Many of the drugs 
themselves can impair other immune parameters, including humoral 
responses and can produce quantitative phagocyte defects. 
 Exogenous administration of glucocorticoids leads to increased 
susceptibility to infection.  The degree of immunosuppression depend 
on the dose and duration of use.  The major effect of steroids on 
granulocyte function is a decrease in chemotactic activity. 
 Radiation therapy has been associated with granulocyte 
dysfunction and delayed wound healing.12 
 Interleukin-2 administration depresses host defense, by 
decreased production of superoxide, decreased chemotaxis, decreased 
FC receptor γ-III expression of granulocytes12 
 In early B cell CLL, the infection risk is mainly related to 
unbalanced immunoglobulin chain synthesis and resultant 
hypogammaglobulinemia. 
In patients having advanced CLL, with purine analog and 
monoclonal agent (rituxumab or alemtuzumab) therapy, neutropenia 
and defects in CMI are additional factors predisposing to infection.13 
 Hodgkins disease, followed by NHL is the most commonly 
encountered malignant disorder associated with impaired CMI, The 
extent of impairment is compounded by the administration of 
immunosuppressive therapy.12 
 In multiple myeloma, Hypogammaglobulinemia and other factors 
associated with aggressive therapy are responsible for defects in 
Humoral immunity.5 Functional neutropenia occur in myelodysplastic 
syndrome. In Aplastic anaemia, bone marrow failure leads to 
pancytopenia.  Neutropenia and abnormal cell mediated immunity 
resulting from therapies (eg. steroid anti thymocyte globulin, 
cyclosporine, bone marrow transplantation) are all risk factors, 
predisposing to infection.12 
 
 
ORGANISMS LIKELY TO CAUSE INFECTION IN 
GRANULOCYTOPENIC PATIENTS5 
Gram Positive Cocci Gram Positive Bacilli Gram Negative Bacilli 
S. epidermidis Diphtheriods E.coli 
S. aureus C. jeikeium Klebsiella sp 
S. viridans  Pseudomonas 
aeruginosa 
Ent. faecalis  Pseudomonas sp. 
Str. pneumoniae  Enterobacter sp. 
  Serratia sp. 
  Acinetobacter Sp. 
  Citrobacter sp. 
 
Fungi 
 Candida sp. 
 Aspergillus sp. 
 Fever is the principal sign of infection in neutropenic patient and 
frequently may be the only evidence of infection.3,2 
Neutropenia 
  Neutropenia is defined as a neutrophil count <500 cells / mm3 or 
< 1000 cells / mm3 with expected decrease to < 500 cells / mm3 within 
48 hours.2 Studies have shown that there is an inverse relationship 
between the number of circulating neutrophils and the incidence of 
infection.  As the neutrophil count decreases to < 1000 cells / mm3, the 
incidence of infections increases markedly.  The risk of severe 
infectious complications such as blood stream infection is greatest when 
the neutrophil count drops below 100 cells / mm3.13 
 The duration of neutropenia is also a major determinant of the risk 
of infection. Profound and prolonged neutropenia (ie<500 cells / mm3 for 
more than 10 days) is considered to be a major risk factor for both 
primary and secondary bacterial or fungal infections.13 
 Thus there are no immunodeficiencies associated to each 
disease, instead several immunitarian deficiencies can be associated in 
a single clinical entity.14 
 Febrile episodes during neutropenia are defined as an oral 
temperature of 38.3°C (100F) in the absence of other non-infectious 
cause of fever such as administration of blood / blood products) 
pyrogenic drugs, cytotoxic therapy (Amphotericin B) the underlying 
disease, thromboembolic, thrombophlebotic or haemorragic events.15 
 The pattern of fever in the presence of neutropenia is nonspecific 
and non pathognomonic of any specific type of infections. 
 Classically infection have been subdivided into three main 
categories.6 
I.  Microbiologically documented infection (MDI) 
 Most episodes of MDI consists of bloodstream infections and may 
be either primary or secondary to a proven focus of infection (eg 
pneumonia, cellulitis, catheter related infection, UTI) and it accounts for 
25-35%16,17 
II.  Clinically documented infections (CDI) 
 Defined by the presence of a site of infection (eg. pneumonia, 
cellulitis, oropharyngeal mucositis, enterocolitis, catheter site infection) 
without microbiological proof of the nature of infection and it accounts 
for 20-30%.16,17 
III.  Fever of unknown origin (FUO) 
 Defined as a febile episode that is not accompanied by clinical or 
microbiological evidence of infection and it accounts for 40-60%.16,17 
 Neutropenic patients may have unusual presentations of infection 
because of their inability to mount an adequate inflammatory response 
and their susceptibility to infection caused by less virulent organism.  If 
not treated promptly, infection in neutropenic patients can progress 
rapidly.18 
Site of infection 
 The most frequent sites of infection in neutropenic cancer patients 
with haematological malignancies by decreasing order of frequency, the 
blood stream, the oralcavity and nasopharynx, the skin, soft tissue, the 
respiratory tract, the gastrointestinal tract, and the urinary tract.6 
Unusual sites of infection include, typhilitis, perirectal infections 
and atypical forms of cellulitis.18 
Blood Stream Infections 
 Nosocomial blood stream infection in neutropenic patients is 
significantly associated with an excess length of hospital stay, extra 
costs, and excess mortality. Severe sepsis and septic shock are closely 
correlated with adverse outcome.14 
 Bacteria are the most frequent blood, isolates, accounting for over 
90%.  Gram positive isolates includes CONS, Viridans Streptococci, 
S.aureus. Among gram negatives E.coli, Klebsiella spp. and other 
enterobacteriaceae are predominant.19 
 Body sites often associated with infection in the neutropenic 
patients are those associated with integumental surface (skin, upper / 
lower respiratory tract, upper & lower gastrointestinal tract). 
Skin and Soft tissue Infections 
 Cellulitis and acute inflammation of the skin are most often 
caused by infection with group A Streptococci / S. aureus.4 
 Although cellulites may be circumscribed in normal hosts it can 
spread in neutropenic patients.  Rapid progression of local infection with 
blood stream invasion and septicemia is frequent.4 
 Patient who are neutropenic and have received antibiotics for 
other reasons may develop cellulitis due to unusual organisms (E.coli, 
Pseudomonas, fungi).4 
 Stomatitis of the oral cavity is a major complication of cancer 
chemotherapy, signs being erythema, edema followed by secondary 
infection further complicating management.4 
 Patients undergoing remission induction for AML or bone marrow 
transplantation with a history of Herpetic stomatitis or who are IgG  
seropositive for Herpes simplex virus are at risk for severe herpetic 
mucositis.20 
 Skin specific syndromes and ecthyma gangrenosum located in 
non pressure areas is often associated with Pseu. aeruginosa 
bacteremia, but may be caused by other bacteria also.4 
Enteric infections 
 Factors favouring enteric infections are mucositis from cancer 
treatments, reduced stomach acidity, reduced intestinal motility, 
reduced mucosal, humoral and cellular immunity.20 
 Ingested microorganism can cause systemic infections in these 
patients even in numbers smaller than the usual infective dose.20 
 Invasive enteric bacterial infection of the gut due to Salmonella or 
Shigella species are relatively uncommon in neutropenic patients.20 
 Two clinical entities to be considered in febrile neutropeunic 
patients with abdominal pain and diarrhoea are toxigenic enterocolitis 
due to toxin elaborated from an overgrowth of clostridium difficile and 
neutropenic enterocolitis (Typhilitis).20 
 Bacteremia with enteric microorganisms (E.coli, Klebsiella 
species Pseu. aeruginosa) is associated with Typhilitis in upto 28% of 
cases. 
Respiratory Tract Infections 
 Damage to local and systemic host defenses of the lung makes 
the immunocompromised patient vulnerable to inhaled microorganisms. 
Neutropenia is associated with gram negative bacilli pneumonia.  
Prolonged neutropenia increases the risk of invasive aspergillosis and 
other unusual mycotic agents. 
Cellular immunodeficiency is associated with intracellular 
microorganisms including Mycobacteria sp. Nocardia sp. Legionella sp, 
Cytomegalovirus. Humoral immunodeficiency predisposes to 
Hemophilus influenzae and S. pneumoniae infection.21 
 Fungal infections are increasing in frequency, among patients 
with haematological malignancies.  The fungi which cause most of the 
infections in cancer patients are Candida spp. and Aspergillus spp. 
Many factors predispose patients to fungal infections, including 
neutropenia, lymphopenia, gastrointestinal ulceration, interavenous 
catheters and steroid therapy.  Candida spp. cause 5 major types of 
infection, dermatitis, thrush, gastro-intestinal, primary organ and 
disseminated infection.  Aspergillus spp. and phycomycetes cause 
pulmonary, disseminated or rhino-cerebral infection. Cryptococcus 
neoformans usually cause meningitis, but may cause pneumonia or 
disseminated infection.22 
 Enhancement of host defenses with growth factors and cytokines 
may decrease the incidence and improve the final outcome of 
respiratory infections in the immunocompromised host. 
 Successful treatment depends on the type of pathogen, status of 
host defense and early appropriate use of ideal antibiotic. Therefore, 
selection of potent, broad spectrum agents when iniating empirical 
antimicrobial therapy in the neutropenic patient is critical.23,24  Hence a 
study of common organisms causing infections in haematological 
malignancy patients and their antibiotic sensitivity pattern is essential for 
effective treatment. 
  
 
 
 
 
 
 
 
 
 
 
 
 
Aims and objectives 
 AIMS AND OBJECTIVES 
 
¾ To isolate and identify the bacterial and fungal agents causing 
febrile episodes in patients with neutropenia following 
chemotherapy for Haematological malignancies. 
¾ To identify bacterial and fungal pathogens in patients with other 
haematological disorders 
¾ To study the antimicrobial susceptibility pattern of isolates 
¾ To evaluate an ideal protocol for standard antibiotic therapy in 
neutropenic patients 
¾ To analyse the correlation between neutrophil counts, etiological 
agents and episodes of infection among different age groups 
¾ To identify factors influencing mortality in these patients 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Materials and methods 
MATERIALS AND METHODS 
Period of Study 
 This prospective study carried out over a period of 1 year from 
April 2006 to May 2007. 
Place of study 
 This study was undertaken at the Institute of Microbiology, 
Madras Medical College, Chennai and The Department of Haematology 
Government General Hospital, Chennai. 
Study Group 
 A total of 94 patients both male and female were included in the 
study comprising of 
 Acute Myeloid Leukemia   47 
 Acute Lymphatic Leukemia  21 
 Chronic Myeloid Leukemia  4 
 Chronic Lymphocytic Leukemia 1 
 Lymphoma     6 
 Haematological disorders  15 
Inclusion criteria 
 All patients having episodes of fever 38.4°C and above and 
having any systemic complaints and / or local sepsis and belonging to 
the following category. 
1. Patient having hematological malignancies on chemotherapy 
2. Patient with neutropenia due to hematological disorders 
          Neutropenia is frequently classified as mild, moderate or severe. 
Mild neutropenia corresponds to an absolute neutrophil count of 
1000-2000 x 109/mm.3 Moderate neutropenia is defined as an absolute 
neutrophil count of 500-1000x109/mm3 and in severe neutropenia the 
absolute neutrophil count is <500 x 109/mm3.20 
Methodology 
i. Collection of specimen 
ii. Macroscopic examination 
iii. Microscopic examination 
iv. Culture procedure 
v. Identification of organisms 
vi. Antibiogram 
vii. Tests for detection of β-lactamase producing organisms 
Collection of Specimens 
Blood 
 After choosing the vein to be drawn, the skin over the 
venepuncture site is disinfected first with 70% alcohol in a circular 
motion.  Allowed to air dry.  Then 2% tincture iodine (or povidone 
iodine) is applied and allowed the iodine to dry on the skin for 1 
minute.25 
 After disinfecting the venepuncture site, about 5 ml of venous 
blood was drawn from three different sites using sterile disposable 
needle and syringe and were innoculated onto 50 ml of BHI broth. 
(Appendix 1) 
 Based upon the clinical manifestation, serum was collected for 
testing antibodies to HIV and HBsAg (Appendix 2) and for serological 
test for enteric fever, brucellosis and leptospirosis. (Appendix 3) 
Peripheral Blood Smear 
 Thick and thin smears were made from the peripheral blood, to 
look for the presence of malarial parasite. 
 Thin film-One drop of blood was placed over the glass slide, with 
the help of spreader at 45° angle, thin smear was made. 
 Thick film-One drop of blood was placed on the same slide on the 
other corner.  By using corner of the spreader circular thick smear was 
made. 
Sputum 
 Patients were instructed to have mouthwash and gargle with 
sterile distilled water and to cough when the sputum was felt in the 
throat, and to spit the material directly into a wide mouthed sterile 
container. 
Tongue ulcer scrapings 
 Material from lesion was collected with sterile swab. 
Pleural Fluid 
 Collected by aspiration with a needle and syringe under aseptic 
precaution. 
Wound swab 
 Using sterile swab the specimens were collected and transported 
to the laboratory without any delay. 
Faeces 
 The specimens were collected in a sterile wide mouthed bottle. 
ii. Macroscopic Examination 
Sputum 
 Sputum was examined for colour and consistency and presence 
of mucus, mucopurulant and frothy material. 
Pleural fluid 
 Aspirated pleural fluid was examined for consistency, colour, 
turbidity and presence of blood. 
Faeces 
 Faeces was observed for the presence of mucus, pus, blood and 
for the segments of tapeworm. 
iii. Microscopic Examination 
Blood 
 Both thick and thin smears were stained by leishman’s method 
(Appendix 4) and examined for malarial parasites. 
Gram stain 
 Smears from sputum, wound swab, tongue scrapings and pleural 
aspirates were all stained by Gram’s method and examined for the 
presence of squamous epithelial cells, polymorphonuclear leucocytes, 
mononuclear leucocytes, gram positive, gram negative bacteria and 
yeast cells. 
Ziehl Neelson Stain 
 Sputum specimens were subjected to concentration technique by 
Petroff’s method. 
Petroff’s method 
 Sputum is incubated with an equal volume of 4% sodium 
hydroxide solution at 37°C with frequent staking till it becomes clear, on 
an average for 20 minutes.  It is then centrifuged at 3000 rpm for 20 
minutes and the sediments neutralised with N/10 Hcl and used for 
preparation of smear.26 
 The smear stained by Ziehl Neelson method and examined for 
acid fast bacilli. 
Faeces 
 Saline and Iodine mount preparation of faeces were done and 
observed under low and high power objectives for the presence of 
trophozoites, ova and cyst. 
iv. Culture Procedure 
 5 ml of blood from 2 sites were inoculated into 50 ml of Brain 
Heart infusion broth.  From the third site 3 ml was inoculated into 
thioglycolate broth (Appendix 1) and 2 ml was used for obtaining serum 
by transfering onto a sterile tube. 
 The blood culture bottles were incubated at 37°C.  Subcultures 
were made at 24 hrs, 48 hrs and after 5 days and on 7th day onto 
MacConkey, Blood agar and Nutrient agar plate (Appendix 5) incubated 
aerobically. Blood agar plate was incubated in 10% Co2 in candle jar. 
 Subcultures from thioglycollate broth were made on neomycin 
Blood agar plates (Appendix 5) and one set incubated aerobically and 
another set incubated anaerobically in McIntosh jar.  Aerobic plates 
were examined at 24 hrs and 48 hrs and anaerobic plates at 72° hrs, for 
growth. 
Sputum 
 Sputum was plated onto MacConkey, Chocolate agar plates. 
(Appendix 5) Incubated at 37°C for 24 hrs.  CAP was incubated in 10% 
CO2 in candle jar. Plates were examined after 24 hrs for the presence of 
growth.  If growth was present isolates were identified based on colony 
morphology, gram stain and standard biochemical reactions. (Appendix 
6) 
Sabouraud’s Dextrose Agar 
 Each sputum specimen was inoculated onto 2 sets of SDA 
slopes, (Appendix 7) one set with 50 mg / 100 ml of cycloheximide 
(Actidione) and 16 µg/ml of chloramphenicol and the other set without 
cycloheximide and chloramphenicol.  One tube from each set was 
incubated at 37°C and the other tube incubated at 25°C. 
 The culture tubes were examined for growth daily for a week, and 
twice a week for further four weeks before discarding it as sterile. 
 If growth was present, the fungal isolates were further identified 
by gram stain and lactophenol cotton blue mount. 
Tongue Scrapings 
 Were inoculated onto 2 SDA slopes without cycloheximide and 
antibiotic and one tube incubated at 25°C and the other at 37°C.  
Examined after 24 hrs for growth.  If growth was seen, it was confirmed 
by Gram stain and LPCB.  Further candida speciation was done by 
germ tube test and sugar assimilation test. 
Pleural fluid was also inoculated onto MacConkey, Chocolate agar 
plates and incubated at 37°C for 24 hrs and observed for growth. 
Wound swabs were inoculated onto MacConkey and Chocolate agar 
plates and thioglycolate broth. 
 Subcultures were made from thioglycolate broth, onto 2 sets of 
Neomycin Blood agar plates and one set incubated at 37°C aerobically 
and another set incubated anaerobically in McIntosh jar.  Plates were 
examined and processed as per routine procedure. 
Faeces was inoculated onto MacConkey and XLD (Appendix 5) plates, 
both directly from specimen and after enrichment in Selenite F broth. 
(Appendix 1) 
 After 24 hrs isolates were identified by conventional Biochemical 
tests and antibiotic susceptibility test was put up as required. 
Detection of Antimicrobial Susceptibility Pattern 
 Antimicrobial susceptibility test was done on Mueller – Hinton 
agar (Appendix 5) by Kirby - Bauer disk diffusion method as 
recommended by NCCLS. 
 Test inoculum 0.5 Mc Farland Lawn culture 
 Incubation – 37°C for 16-18 hrs 
 Control Strains: 
  Staph aureus – ATCC 25923 
  E.coli ATCC – 25922 
  Pseudomonas aeruginosa ATCC 27853 
The antibiotics used 
Inhibition zone in mm 
Antimicrobial Agent 
Resistant Intermediate Sensitive 
Penicillin G (IOU) < 20 21-29 > 30 
Ampicillin (10 mg) < 20 21-29 > 30 
Oxacillin (1 mg)   > 13 
Gentamicin (10 mcg) < 12 13-14 > 15 
Amikacin (30 mcg) < 14 15-16 > 17 
Ciprofloxacin (5 mcg) < 15 16-20 > 21 
Oflaxacin (5 mcg) < 12 13-15 > 16 
Cefotaxime (30 mcg) Gm +ve < 14 
Gm –ve < 10 
15-22 
11-15 
> 23 
> 16 
Cefaperozone – 
Sulbactam (75mcg/30 
mcg) 
< 15 16-20 > 21 
Imipenem 10 mcg < 13 14-15 > 16 
Vancomycin (30 mcg)   > 15 
  
The diameters of the zones of inhibition were interpreted 
according to NCCLS standards for each organism.28 
Identification of β-lactamase production 27 
 The determination of β-lactamase production was done by 
iodometric method. 
Procedure 
Iodometric method 
Requirements 
i. 1% soluble starch solution prepared by dissolving the starch at 
100°C. 
ii. Iodine reagent consisting of 2.03g iodine and 5.32 g potassium 
iodide in 100 ml distilled water. 
iii. Microtitre plate 
Procedure 
 From an overnight incubation culture of the test organism, a 
heavy suspension was made (containing 109CFU/ml) in 100 mM sodium 
phosphate buffer at pH 7.3 containing penicillin 6g/litre, along with 
positive and negative controls. 
 Positive Control – E.coli ATCC 35218 
 Negative Control – E.coli ATCC 25922 
 The test and the control organisms were inoculated into the wells 
of a microtitre plate.  After incubation for 1 hr at 37°C, two drops of 
freshly prepared 1% soluble starch solution was added to each well.  A 
drop of Iodine reagent was then added.  If blue colour was lost within 10 
minutes, the presence of β-lactamase was inferred.  If however, the blue 
persisted, the culture was considered to be β-lactamase negative. 
DETECTION OF EXTENDED-SPECTRUM BETA-LACTAMASES 
(ESBL) 
 ESBLS are enzymes that mediate resistance to extended-
spectrum (third generation) cephalosporins (eg. ceftazidime, cefotaxime 
and ceftriaxone) and monobactams (eg. aztreonam) but do not affect 
cephamycins (eg. cefoxitin) 
 Cefpodoxime and ceftazidime have been proposed as indicators 
of ESBL production. 
METHODS ADOPTED FOR DETECTION 
 Isolates showing a zone of inhibition < 27 mm for cefotaxime (30 
mcg were tested for ESBL production as per NCCLS criteria, using 
standard control strains.29 
1. COMBINED DISC METHOD 30 
 Latest guidelines by NCCLS recommend a combined disc method 
as an indicator of ESBL production.  For disc diffusion testing,  ≥ 5mm 
increase in zone diameter of the antimicrobial agent tested in 
combination with betalactamase inhibitor (eg. clauvulanic acid, 
sulbactam) verses its zone when tested alone confirms an ESBL 
producing organism. 
 Combined Disc method using cefaperazone (75 mcg) and 
cefaperazone – sulbactum (75 mcg / 30 mcg) was performed for 
phenotypic confirmation of ESBL production. 
2. DOUBLE DISC SYNERGY TEST 30 
 In this test a lawn of the test strain on Mueller – Hinton agar was 
exposed to discs of ceftazidime (30 mcg) and augmentin (20 mcg 
amoxycillin / 10 mcg clavulanic acid) arranged in pairs.  The discs were 
arranged so that the distance between them is approximately twice the 
radius of the inhibition zone produced by the cephalosporin tested on its 
own.  After overnight incubation, the test strain was an ESBL producer if 
the inhibition zone around the cephalosporin disc was extended on the 
side nearest the augmentin disc. 
 
  
 
 
 
 
 
 
Results 
RESULTS 
Table 1 
Sex wise Distribution of patients with Haematological diseases 
(n=94) 
S. No. Diseases Male Female Total 
1 AML 29 18 47 
2 ALL 13 8 21 
3 CML 2 2 4 
4 NHL 4 2 6 
5 CLL 1 - 1 
6 H. Disorders 9 6 15 
  58 36 94 
 
Male preponderance was observed in patient with AML and ALL 
No Significant difference was observed In Hematological Disorders. 
 
 
 Table 2 
Age and Disease wise Distribution of patients with 
Haematological diseases 
(n=94)  
Age AML ALL NHL CML 
H. 
Disorders
CLL 
Group M F M F M F M F M F M F 
Total
10-20 5 3 6 5 - 1 - - 1 - - - 21 
21-30 9 5 3 2 3 - 2 1 4 3 - - 32 
31-40 5 4 2 1 - 1 - 1 1 1 - - 16 
41-50 6 3 1 0 1 - - - 1 - - - 12 
51-60 2 2 - - - - - - 2 1 1 - 8 
61-70 2 1 1 - - - - - - 1 - - 5 
Total 29 18 13 8 4 2 2 2 9 6 1 - 94 
 
More then 50% of patients were below 30 years of age 
Maximum Incidence in the age group of 21 – 30 
 Table 3 
Episodes of infections in patients with Haematological diseases 
(n=94) 
Episodes No. of Patients Total episodes  
1 78 78 
2 12 24 
3 3 9 
4 1 4 
Total 94 115 
 
This works to 1.22 episodes of infection per patient per year. 
 Table 4 
Comparative Analysis of Absolute Neutrophil count (ANC) vs 
Number of episodes vs Number of Isolation 
(n=115) 
ANC Number of 
Episodes 
Isolates 
Positive 
% 
>500 m3 30 18 60 % 
500 – 1000  12 4 33 % 
1000 – 2000  14 2 14 % 
>2000 59 9 15 %  
Total 115 33 28.6 % 
 
Isolation rate was found to be higher in patients with ANC less than 
500/mm3 of blood. 
 Table 5 
Cullture positivity in various Samples during febrile episodes in 
the study group 
(n=115) 
Sample Number tested Bacterial  
isolates  
Fungal  
isolates 
Blood 115 19 - 
Sputum 12 5 2 
Oral ulcer 5 2 - 
Wound 5 3 - 
Tongue scraping 1 - 1 
Faeces 1 1 - 
Pleural fluid  1 - - 
Sputum AFB  12 - - 
 
Maximum number of isolates were from blood. 
 Table 6 
Isolation of pathogens in patients with various 
Haematological diseases 
(n=94) 
Diseases  No of Patient Bacterial    Fungal  Total 
AML 47 14 2 16 
ALL 21 7 - 7 
CML 4 2  2 
H - Disorders  15 4 1 5 
NHL 6 2 - 2 
CLL 1 1 - 1 
 94 30 3 33 
 
Maximum number of isolates were from patients with AML 
DISTRIBUTION OF MICROBIOLOGICALLY DOCUMENTED 
INFECTION IN THE STUDY GROUP
65%
32%
3%
No growth Bacterial Fungal
 
 Table 7 
Blood culture Isolates from patients with Haematological diseases 
(n=19) 
Isolates Number 
S. aureus 5 
S. epidermidis 6 
Micrococcus 1 
Diphtheroid 1 
E. coli 2 
K. pneumoniae 1 
Pseu. aeruginosa 2 
Acinetobacter Sp 1 
Total 19 
 
Predominant isolates from blood were S. epidermidis (31.6%) and 
Staphylococcus aureus (26.3%). 
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pneumoniae
K.oxytoca Pseu.
aeruginosa
Acinetobacter
Sp
6 6
1 1
3
6
1
5
1
0
1
2
3
4
5
6
N
U
M
B
E
R
ORGANISMS
BACTERIAL PROFILE OF CULTURE POSITIVE CASES IN THE 
STUDY GROUP
 
BACTERIAL PROFILE OF BLOOD CULTURE POSITIVE CASES IN 
THE STUDY GROUP
5
6
1 1
2
1
2
1
0
1
2
3
4
5
6
7
S. aureus S. epidermidis Micrococcus Diphtheroid E. coli K.
pneumoniae
Pseu.
aeruginosa
Acinetobacter
Sp
ORGANISMS
N
U
M
B
E
R
 
Table 8 
Analysis of Organisms Isolated from Different 
Specimens and Sites 
(n=33) 
Organism  Blood Sputum Oral 
ulcer 
Skin 
wound 
Tongue 
scraping  
Faeces Total
S. aureus 5 1 - - - - 6 
S. epidermidis 6 - - - - - 6 
Micrococcus 1 - - - - - 1 
Diphtheroid 1 - - - - - 1 
E – coli 2 - - - - 1 3 
K. pneumoniae 1 2 1 2 - - 6 
K. oxytoca   - 1 - - - - 1 
Pseu. aeruginosa 2 1 1 1 - - 5 
Acinetobacter Sp 1 - - - - - 1 
Apergillus flavus - 2 - - - - 2 
Candida albicans - - - - 1 - 1 
Total 19 7 2 3 1 1 33 
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Table 9 
Antibiotic-Susceptibility Pattern of Isolates from Study Group 
(n=30) 
Organism Penicillin Vanco-
mycin 
Amikacin Genta- 
micin 
ciprofloxacin Ofloxacin Cefotaxime Cefaperozone 
-sulbactam 
Imipenem Piperacillin 
Tazobactum
S. aureus 6 - 6 6 - 3 (50%) 6  5 (83%)   
S. epidermidis 6 - 6 6  3 (50%) 46 (66%) 1 (16.6%) 5 (83%)   
Micrococcus 1 3 (50%) 1 1 - 1 1 1 1   
Diphtheroid 1 - 1 1 - 1 - - 1   
E. coli 3 -  3 3 2 (66%) 3 (50%) - 2 3 3 
K. pneumoniae 6   4 (66%) 3 3 2 2 (33.3%) 6 6 6 
K.Oxytoca 1   1 - 1 1 2 1 1 1 
Pseu. aeruginosa 5   5 4 3 (60%) 1 2 5 5 5 
Acinetobacter Sp 1   1 1 1 1 1 1 1 1 
Amikacin was found to be the most useful antibiotic with 93% effectiveness. 
Table 10 
Analysis of Infective causes for Mortality in the Study group 
(n=94) 
Total 
Number of 
Patient 
Number of 
patients died 
Death due to 
Infective 
Cause 
Gram negative 
Bacilliin blood 
Gram positive 
organism in 
Blood 
Gram negative 
organism in other 
site 
Systemic 
Fungal 
Infection 
No organism 
Isolated 
94 8 7 3 1 2 1 1 
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Table 11 
Percentage of β-Lactamase production in Gram positive isolates 
from patients with Haematological diseases 
(n=12) 
Organism 
Number of  β-
lactamase Producers
Percentage 
S. aureus (6) 3 50 
S. epidermidis (6) 4 66.6 
 
Table 12 
Percentage of ESBL Productions in Gram negative isolates from 
patients with Haematological diseases 
(n=14) 
Organism 
Number of ESBL 
Producers 
Percentage 
E-coli (3) 1 33 
Klebsiella pneumoniae (6) 3 50 
Pseudomonas aeruginosa (5) 1 20 
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Table 13 
Antibiotic susceptibility pattern of Multidrug Resistant Isolates in 
patients with Haematological diseases 
(n=4) 
Site  of 
Isolation  
Organism  Number  
isolated 
Résistance 
pattern  
Sensitivity 
pattern   
Blood K. pneumoniae 1 AK, Cip, OF GM, CEF Cef – Sul, Imi 
Sputum K. pneumoniae 1 AK, Cip, GM, OF , CEF Cef – Sul, Imi 
 Psendomonas aeruginosa 1 
GM, OF, Cip, 
CEF AK, Cef – Sul, Imi 
Pus K. pneumoniae 1 GM, OF, Cip, CEF AK, Cef – Sul, Imi 
 
All the 4 isolates were found to be ESBL producers 
AK  -  Amikacin 
Cip  - Ciprofloxacin 
OF  - Ofloxacin 
GM  - Gentamicin 
CEF  - Cefotaxime 
Cef - Sul - Cefaperazone – sulbactam 
Imi  - Imipenem  
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Discussion 
 64
DISCUSSION 
 The study undertaken by the Institute of Microbiology, Madras 
Medical College, Chennai, among patients admitted in the Department 
of Haematology, Government General Hospital, Chennai with 
haematological malignancies and disorders showed the following 
results. 
 This study was undertaken in 94 patients with a total of 115 
episodes of febrile neutropenia. 
 Cases were distributed between the age group 10-70 years. 
Majority of patients were < 30 yrs of age with a maximal incidence 
between 21-30 yrs. This coincides with the accepted age group as 
described by Robbins, et al.10 
 50% of patients with acute lymphatic leukemia fell in the 10-20 
years of age group. According to Robbins et al ALL is frequently 
diagnosed in patients <15years of age. 10 
 There was a male preponderance constituting nearly three fifth of 
the total study population. Davidson states that males are affected more 
frequently than females, the ratio being about 3:2 in Acute Leukemia 2:1 
in chronic lymphocytic leukemia and 1.3:1 in chronic myeloid 
leukemia.11 
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 78 Patients suffered from a single episode of fever during the 
course of study, 12 patients suffered two such episodes and 3 patients 
had three episodes and one patient had four episodes of fever. 
 This works out to 1.22 episodes of infection per patient per year. 
 Robert B. Jerknes et al quotes an overall incidence of 0.25 – 0.50 
episodes per patient per year increasing up to 1.8 episodes per year in 
patients who have advanced disease.31 
 Fever was the main presenting manifestation in 73% of patients in 
this study. This correlates well with the study by Khan M.A et al (2002) 
who reported, that 86% of patients presented with fever in the similar 
study group.32 
 Other presenting manifestations were, pneumonia in 13% of 
patients, skin bleb and oral ulcer each in 5% of patients, gastroenteritis, 
pleural effusion and oral candidiasis each in 1% of patients. These 
findings were similar to the study by Jagarlamudi R. et al (1998) who 
reported that respiratory infections were the most common infections 
next to fever followed by skin, soft tissue, GIT and genitourinary tract 
infections in order of decreasing frequency. 33 
 In the present study microbiologically documented infection rate 
was 35% of which 32% was bacterial and 3% was fungal in etiology. 
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This correlates well with the study of A.K. Bilolikar et al (2000), where 
Microbiologically Documented Infection rate was 32%. 34 
Meunier et al had reported an incidence of 25–30% 
microbiologically documented infection in neutropenic patients.35 
Das P.K. et al had reported that in his study Bacterial infection 
predominated followed by fungal and parasitic infection.36 
 In this study bacteraemia was observed in 16.5% of febrile 
episodes. Kumar L et al (1998) reported 13.72% of septicemic rate in 
his study at department of medical oncology ALLMS, New Delhi. 37 
 Khan M.A. et al, (2003) reported septicemia in 16.1% of patients 
in his study.32 
 Gram positive pathogens are the predominant cause of infection 
in Neutropenic patients.38 
 In this study, Bacteraemia due to gram positive organisms 
accounts to 68.4% and due to gram negative organism accounts for 
31.6%.  This correlates well with the study of Jagarlamudi R. et al, 
2006.33 
 Staphylococcus epidermidis was isolated in 31.6% and 
Staphylococcus aureus was isolated in 26.3% of all bacteraemias. 
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This Correlates with the increasing incidence of CONS 
bacteraemia in many centres.19,39  
The most prevalent species of CONS was S. epidermidis. 40 
The spectrum of gram negative isolates includes, E.coli (2) 
Pseudomonas aeruginosa (2), K.pneumoniae (1), Acinetobacter Sp. (1). 
This correlates well with the study of Cordonnier C. et al, (2005) 41 and 
Kumar. L. et al, (2002)37 
Patient with gram negative bacteraemia have a poor prognosis 
and higher mortality 42,43.  Hence all regimens are chosen to combat 
gram negative sepsis.44 This may explain the shift from gram negative 
bacteraemia to isolation of gram positive organisms. 
 Factors considered responsible for the shift towards gram positive 
isolates include.4 
1. Aggressive chemotherapy (Where ever cytarabine is given) 
2. Radiotherapy causing mucositis 
3. Profound and prolonged neutropenia 
4. Unrecognized herpetic infection of the mucous membrane 
5. Increased use of long dwelling intravenous catheters      
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6.  H2 antagonists 
7. Use of cotrimoxazole and newer quinolones in neutropenic 
patients (Giamorellau and Antoniadou Pg 460). 
Patients included in this study received H2 antagonists along with 
chemotherapy. 
 Fungal isolates in this study were from sputum and from tongue 
scrapings. Two were Aspergillus flavus and one was Candida albicans. 
No fungaemia was observed. 
 This is similar to the findings of Pagano L et al (2006) that, most 
common pathogen associated with fungal pneumonia are Aspergillus 
and Zygomycetes.45 
 The study population were put on regimen consisting of 
Cefotaxime which was changed to Fluconazole, Piperacillin-
Tazobactam and Amikacin if the patient remained febrile and showed 
signs of failure to respond to the first regimen. 
 This may be responsible for the absence of fungaemia in this 
study. 
 No anaerobic organisms were isolated in this study. This reflects 
the less percentage of anaerobes causing infection in these neutropenic 
patients. 43 
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Sputum specimens from patients with clinical pneumonia were 
subjected to sputum culture. Out of the 12 sputum samples, 3 gram 
negative isolates and one gram positive isolate and 2 isolates of 
Aspergillus flavus were obtained. This workout to 58% of 
microbiologically documented infection in pneumonia. This finding is 
similar to Fernandez et al (1999) 46. This also reflects the fact that 
interstitial pneumonia of unknown cause could develop in patients with 
various hematological malignancies especially at recovery phase of 
chemotherapy.47 
None of the 12 sputum were positive for AFB by Ziehl Neelson 
staining method. This may have been due to the fact that most of the 
patient had received broad spectrum antibiotic (including Amikacin) as 
part of empirical antibiotic therapy, to which the AFB may have been 
sensitive. 
 From one patient, in the first febrile episode Klebsiella 
pneumoniae was isolated from the sputum, and in the second febrile 
episode Aspergillus flavus was isolated. 
 This reflects the role of prolonged neutropenia and Antibiotic 
prophylaxis as predisposing factors for systemic fungal infection by 
replacing the normal flora.48 
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Bacterial infections are a major cause of illness and death.55 
Septic shock and death due to Blood Stream Infection occurred 
more frequently in the group of neutropenic patients.50 
 In this study out of 94 patients, 8 died with a mortality rate of 
8.5%. This correlates with the finding of Jagarlamudi. R. et al (2006)33,51 
 In the present study the important risk factor for mortality was 
infection, in 7 out of 8 patients (87%) which correlated with the study by 
Robert Bjerknes in which Infection alone accounted for 70% of all 
deaths.31 
 Out of the 5 gram negative isolates associated with mortality 4 
isolates were ESBL producer and in these 4 isolates 3 were multidrug 
resistant. Mortality due to multidrug resistant gram negative 
bacteraemias was higher in comparison to bacteraemias due to 
susceptible organism53. This correlates well with the findings of 
Krcmeryr. et al (1998)52 
 One patient died with systemic fungal infection. Invasive 
pulmonary aspergillosis is a major cause of morbidity and mortality in 
neutropenic patients.50 
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 Since chemotherapy induced neutropenia is more severe in 
elderly patients, increasing age was associated with increased mortality 
from bacteremia in patients with haematological malignancies.55 
 In this study, 85% of all deaths occurred in the age group 
between 41-50 years. This correlates well with the study of Norgaard M. 
et al. (2006).55 
 In the present study, 67% of bacterial isolates and all the 3 fungal 
isolates were obtained from patients with ANC less than 1000/mm3 of 
blood. 
 Absolute neutrophil counts have been found to be the most useful 
prognostic indicator for development of infection. 
 Giamarellou and Antoniadou regard neutrophil counts less than 
100 / mm3  as having high risk of infections and mortality.49 
 D.Hiwase, A.Mukhopadhya et al report an increased risk of 
infection at counts <1000 /mm3 with life threatening infection at levels of 
100 /mm3  35. 
 Since increased duration of neutropenia leads to risk of infection, 
it is a universal practice to start the patients on prophylactic empirical 
antibiotic therapy along with antifungals.  
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 Antibiogram was done for the 30 bacterial isolates and 
susceptibility pattern noted. 
 Amikacin was found to be the most effective antibiotic with 93% 
sensitivity to all the isolates. This is similar to the finding of A.K.Bilolikar 
et al (2000) 34 
 Cefaperazone-sulbactam was 90% sensitive except 2 isolates of 
gram positive cocci and one isolate of E-coli. 
Only 37% of all isolates were sensitive to cefotaxime. 
 80% of isolates of Staphylococcus aureus and 50% of 
S.epidermidis isolates were found to be resistant to oxacillin. Out of this 
50% of S.aureus and 66.6% of S.epidermidis were found to be β – 
Lactamase producers. 
 This is in accordance with the findings of Kirby JT, et al (2006). 58 
 Three isolates of Klebsiella pneumoniae from blood, sputum and 
pus and one isolate of Pseudomonas aeruginosa from sputum were 
found to be multidrug resistant. All these four isolates and one isolate of 
E.coli from blood were found to be ESBL – producers. 
 All the gram positive organisms including Methicillin resistant 
isolates were sensitive to Vancomycin 56,57  This finding was found to be 
statistically significant with p value 0.003. 
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All the gram negative organism including ESBL producers were 
sensitive to Imipenem and Piperacillin-Tazobactam combination.  This 
was found to be statistically significant with p value 0.01. 
 Out of 4 gram negative bacterial isolates from sputum 2 were 
found to be ESBL producers. This is similar to the study of S.Shawgi  
et al (2004) 59  
These organisms are resistant to all cephalosporins and exhibit 
varying and unpredictable degrees of sensitivity to aminoglycosides and 
quinolones. The carbapenems are active against these pathogenes 44. 
This points out to the emergence of ESBL producing organisms as an 
important cause of infection in these patients. This also highlights the 
importance of using antibiotics that are capable of neutralising the ß–
lactamase produced by these organisms and incorporating them into 
newer empirical antibiotic combinations.  
 Timely identification of the causative organisms aids in the 
successful management of these patients. 
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Summary 
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SUMMARY 
¾ In the present study undertaken in patients with Haematological 
malignancies and disorders associated with neutropenia, more 
than 50% of patients were below 30 years of age. 
¾ Male preponderance was observed in patients with AML and ALL 
¾ Infection rate was found to be 35%. 
¾ Bacterial infections were predominant constituting 32% followed 
by fungal infection 3%. 
¾ Bacteraemia was observed in 16.5% of microbiologically 
documented infection. 
¾ 68.4% of bacteraemias were due to Gram positive cocci and 
31.6% of bacteraemias were due to Gram negative bacilli. 
¾ Staphylococcus epidermidis were isolated in 31.6% and 
Staphylococcus aureus were isolated in 26.3% of all 
bacteraemias. 
¾ 80% of staphylococcus aureus isolates and 50% of S.epidermidis 
Isolates were Methicillin resistant. 
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¾ All the Methicillin resistant isolates were sensitive to Vancomycin 
¾ 31.25% of Gram negative isolates were found to be ESBL 
producers.  All ESBL producers were sensitive to Imipenum, 
Piperacillin-Tazobactam 
¾ Multidrug resistance was observed in 3 isolates of Klebsiella sp 
and one isolate of Pseudomonas sp. 
¾ Amikacin was effective against most of the isolates (96%) 
¾ Cefaperozone-sulbactam and Ofloxacin were found to be the 
other effective antibiotics 
¾ There was no significant difference in the infection rate in 
patients with Haematological malignancies and disorders. 
¾ Absolute neutrophil count < 500/mm3 was found to be an 
important risk factor for infection. 
¾ The overall mortality was 8.5%. Infection was the major risk 
factor for mortality in 87% of cases of death. 
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Conclusion  
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CONCLUSION 
¾ Bacterial infections are the major cause of morbidity and 
mortality in patients with haematological malignancies during 
chemotherapy induced neutropenia, and in patients with 
Haematological disorders associated with neutropenia. 
¾ In this study, the spectrum of isolates among febrile 
neutropenic patients, appears to be shifting towards Gram 
positive microorganisms. 
¾ Therapy induced neutropenia is the most important risk factor 
for infectious complications in patients with haematological 
malignancy. 
¾ Increasing age was found to be associated with increased 
mortality from bacteraemia. 
¾ Mortality due to multidrugresistant Gram Negative bacteraemia 
was higher in comparison to bacteraemia due to susceptible 
organisms. 
¾ Since bacterial infections were predominant cause of mortality, 
close monitoring of infection should be done by repeated blood 
cultures, and emergence of drug resistance prevented by 
doing periodical modification of empiric antibiotic regime. 
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Annexure 
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PROFORMA 
Name: In Patient No: 
Age: Address: 
Sex: Occupation: 
 Diagnosis: 
 
Presenting Complaints 
Duration of illness 
Previous History of similar illness or treatment 
Personal History 
Family History 
Clinical Examination –  General Examination 
Systemic examination 
Diagnosis 
Treatment 
 Antibiotics 
 Chemotherapy 
 Radiotherapy 
 Bone marrow transplantation 
Laboratory Investigations 
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1. Complete Hemogram 
     Total count, Differential count, Hemoglobin percentage,    
     Packed cell volume, Platelet count, 
     2. Biochemical tests 
3. Microbiological Methods 
Microscopy – Gram stain 
           Culture 
Antimicrobial Susceptibility test 
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PROCESSING OF SAMPLE 
 
Blood 
 
 
 
5 ml from 3 different sites, inoculated into 50 ml of BHI and Thioglycolate broth 
 
 
 
Incubated at 37°C 
 
 
 
Examined for signs of growth 
 
 
 
Subculture from 
 
 
 
BHI 
         Thioglycollate broth 
 
 
MAC and NA    BAP    Neomycin blood agar plate 
 
 
at 37°C for 48 hrs   at 37°C in CO2  Incubated at 37°C in 
     (10%) for 48 hrs  anaerobic environment 
         for 72 hrs 
 
 
Examined for growth   Examined for growth  Examined for growth 
 
 
LF & NLF    Morphology, Hemolysis 
 
 
Biochemical tests were performed to identify the isolate 
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Oral Ulcer / Wound Swab / Pleural fluid 
 
 
MAC      CAP   Thioglycolate broth 
 
 
at 37°C for 48 hrs   at 37°C with 10% CO2 Neomycin BAP 
      for 48 hrs 
 
 
     Examined for growth  at 37°C for 72 hrs 
         in anaerobic environment 
 
 
     Colony Morphology,  
     Gram stain 
Biochemical Tests  Examined for growth 
 
 
 
 
Sputum 
 
 
 
MAC    CAP     SDA 
 
 
at 37°C  at 37°C  one set with   one set without 
for 48 hrs  with 10% CO2  cycloheximide   cycloheximide 
   for 48 hrs  and chloramphenicol  and chloramphenicol 
 
 
 
 
  
Examined for growh    Incubated at 25°C  at 37°C 
 
 
 
Colony Morphology,  
Gram stain        Examined for growth 
Biochemical Tests 
 
         Gram stain 
         LPCB mount 
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APPENDIX 1 
Brain Heart Infusion Broth (BHI) 
 This is reconstituted from the dehydrated form according to the 
manufacturer’s instructions 
     gm / litre 
Calf brain infusion  - 200.00 
Beef infusion  - 250.00 
Proteose peptone  - 10.00 
Dextrose   - 2.00 
Sodium chloride  - 5.00 
Disodium phosphate - 2.50 
Final pH 7.4 ± 0.2 
Preparation 
 37 gms were suspended in 1000 ml distilled water and dispensed 
into bottles.  They were sterilized by autoclaving at 121°C (15 lbs 
pressure) for 15 min. 
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Thioglycolate Broth 
Yeast extract   - 5 g 
Casein hydrolysate  - 15 g 
Glucose    - 5.5 g 
L.cystine    - 0.5 g 
Agar     - 0.75 g 
Sodium chloride   - 2.5 g 
Sodium thioglycollate  - 0.5 g 
Resazurin sodium solution 
1 in 1000, freshly prepared - 1 ml 
Distilled water   - 1 litre 
 All the ingredients other than thioglycollate and resazurin were 
dissolved in distilled water by steaming at 100°C.  Next thioglycollate 
was added, pH adjusted to 7.3.  Then resazurin solution was added, 
mixed thoroughly, distributed in glass tubes and sterilized at 121°C for 
15 min. Cool at once to 25°C and stored in the dark. 
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Selenite F Broth 
Sodium hydrogen selenite  4 g 
Peptone     5 g 
Lactose     4 g 
Disodium hydrogen phosphate  9.5 g 
Sodium dihydrogen phosphate  0.5 g 
Sterile water     1 litre 
 All the ingredients were dissolved in sterile water with sterile 
precautions.  The yellowish solution in about 10 ml amounts distributed 
into screw-capped universal bottles.  Steamed for 20 min at 100°C      
pH adjusted to 7.1. 
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APPENDIX 2 
Elisa for HBs Ag (Microscreen Elisa test kit) 
1. All the reagents of the kit were brought to room temperature 
except colour reagent. 
2. 100 µL of sample diluents was added to all wells except blank 
well. 
3. 100 µL of negative, positive controls and samples were added to 
the respective wells. 
4. Incubated at room temperature (20-30°C) for 60 minutes. 
5. The well contents were discarded and washed 5 times with 30 
seconds soak time at each step. 
6. 50 µL of conjugate stabilizer and 100 µL of conjugate was added 
to all wells except blank well and incubated at room temperature 
for 30 min. 
7. It was washed 5 times. 
8. 100 µL of colour reagent was added to all wells and incubated at 
room temperature in dark for 30 min. 
9. 100 µL of stop solution was added to all wells 
10. Results were read at 450 nm. 
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Test validity: Test was valid when 
  Negative control < 0.2 
  Positive control > 1.00 
  Reagent blank < 0.100 when read in bichromatic mode  
(450-630 nm) 
Cut off calculation 
 The cut off was calculated based on the mean absorbance of 3 
negative controls and addition of a factor 0.10 ie. 
 Cutoff = NCX + 0.10 
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Interpretation of results 
1. All samples with absorbance less than out on value were 
considered non reactive for HBs Ag. 
2. Samples with absorbance more than cut off value were 
considered reactive 
ELISA for HIV (Microlisa – HIV) 
1. 100 µL of sample diluent was added to A1 well as blank 
2. 100 µL of negative control was added to B-1 and C-1 wells 
3. 100 µL of positive control was added to D-1, E-1 and F-1 wells 
4. 100 µL of sample diluent was added in each well starting from   
G-1 followed by 10 µL of sample was added. 
5. Applied cover seal and incubated at 37°C for 30 min. 
6. The well contents were discarded and washed 5 times with 30 
seconds soak time at each step, with working wash solution. 
7. 100 µL of working conjugate solution was added to each well 
including A-1. 
8. Applied cover seal, incubated at 37°C for 30 min 
9. Well contents were aspirated and washed for 5 times 
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10. 100 µL of working substrate solution was added in each well 
including A-1 
11. Incubated at room temperature for 30 min in dark (20-30°C) 
12. 50 µL of stop solution was added to all wells. 
13. Read absorbance at 450 nm within 30 minutes in ELISA 
READER after blanking A-1 well. 
Cut off calculation 
 The cut off value is calculated by adding mean negative control 
(NCx) and Mean Positive Control (PCx) as and the sum is divided by 
six. 
     NCx + PCx 
 Cut off value =  
      6 
Interpretation of Results 
 Test specimens with absorbance value less than the cutoff value 
are non-reactive and considered as negative for anti-HIV 
 Test specimens with absorbance value greater than or equal to 
the cut off value are reactive for anti-HIV 
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APPENDIX 3 
Widal Agglutination test 
Doubling dilution of serum was done for O,H,AH and BH from 1:25, 
upto 1:400 
Antigen controls were also putup 
Equal quantity of corresponding antigen was added 
Incubated overnight at 37°C 
Results were read for ‘H’ and ‘O’ agglutinin 
 
 The antigens used S.typhi O, S.typhi H, S.paratyphi AH 
S.paratyphi BH were obtained from King Institute of Preventive 
medicine (KIPM), Guindy. 
Interpretation of results 
 ‘H’ agglutination seen as formation of loose, cotton wooly clumps 
 ‘O’ agglutination seen as granular deposit at the bottom of the 
tube 
Antigen controls with no agglutination seen as compact button at 
the bottom of the tube. 
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The criteria for diagnosis were, 
 ‘O’ agglutination titre of ≥ 1 in 100 
 ‘H’ agglutination titre of ≥ 1 in 200 
MACROSCOPIC SLIDE AGGLUTINATION TEST (MSAT) 
FOR LEPTOSPIROSIS 
 MSAT was performed using pooled suspension of leptospiral 
killed antigens.  The following leptospiral serogroups were used 
Icterohaemorrhagiae, Autumnalis, Australis, Hebdomadis, Pomona, 
Patoc, Lousiana, Grippotyphosa. 
Procedure 
 8 µL of phosphate buffered saline and 5 µL of patients serum was 
placed on a depression slide and 12 µL of heat killed pooled antigen 
was added. 
 The slide was rotated at 180 rpm for 4 min on a rotator.  It was 
examined macroscopically for the presence of agglutination and 
confirmed by DFM.  Positive and negative controls was also put up. 
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The results of MSAT were read as follows: 
Negative : No agglutination and uniformity of serum antigen mixture 
1+  : 25% agglutination 
2+  : 50% agglutination 
3+  : Obvious agglutination but partial clearing of suspension 
4+  : Clumps of agglutination with complete clearing of leptospiral  
antigen suspension.  An agglutination of  ≥ 2+ is 
considered as positive. 
STANDARD AGGLUTINATION TEST (SAT) 
FOR BRUCELLOSIS 
 Two-fold dilutions of serum was made from 1 in 20 to 1 in 640 in 
0.4% phenol saline for Br.melitensis and Br.abortus. Antigen controls 
were also putup. 
 Equal quantity of standardized antigen suspension was added 
 Incubated at 37°C 
 Results were read after 48 hrs 
 The antigens were obtained from king institute of preventive 
medicine Guindy. 
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Interpretation 
 Reactions of partial or complete clearing with agglutination visible 
by the naked eye should be reported as positive. 
 Controls with no agglutination seen as compact button at the 
bottom of the tube. 
 A titre of 160 or more is considered positive. 
 
APPENDIX 4 
Leishman’s stain 
Ingredients 
 0.15 gm of tablet 
 Dissolve in 100 ml of absolute methyl alcohol 
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APPENDIX – 5 
Blood Agar 
 Sterile defibrinated sheep blood  - 10 ml 
 Nutrient Agar (melted)   - 100 ml 
 Sterile Nutrient agar was melted cooled to about 45-50°C, 7-10ml 
of sterile defibrinated sheep blood was added.  Mixed well and 15 ml of 
blood agar was poured in petri distress. 
MacConkey Agar 
Peptone    - 20 g 
Sodium taurocholate  - 5 g 
Water     - 1 litre 
Agar     - 20 g 
Neutral red solution 
 2% in 50% ethanol   - 3.5 ml 
 lactose, 10% aqueous solution - 100 ml 
 All the ingredients except lactose and neutral red were dissolved 
in distilled water by heating.  pH adjusted to 7.5.  Lactose and neutral 
red were added and sterilized by autoclaving at 121°C for 15 minutes. 
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Nutrient Agar 
      Gms / litre 
Peptic digest of animal tissue - 5.00 
Beef extract    - 1.50 
Yeast extract   - 1.50 
Sodium chloride   - 5.00 
Agar     - 15.00 
28.0 grams were suspended in 1000 ml of distilled water.  Boiled 
to dissolve the medium completely.  Final pH adjusted to 7.4 ± 0.2 
sterilized by autoclaving at 121°C for 15 minutes. 
Neomycin Blood agar (NBA) 
Nutrient Agar  - 100 ml 
Blood    - 7 ml 
Neomycin 1% solution - 0.25 ml 
Sterlized nutrient agar, cooled to 45-50°C, then sterile blood and 
neomycin solutions were added.  Mixed thoroughly and poured 25 ml 
per plate. 
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Chocolate Agar Plate 
 Sterile Refibrinated blood - 10 ml 
 Nutrient Agar (Melted)  - 100 ml 
When the temperature was about 75°C, sterile blood was added 
with constant agitation, in the water bath.  Heating was continued till the 
blood becomes chocolate brown in colour. Cooled to about 50°C and 
poured about 15 ml into petri dishes. 
Xylose lysine deoxycholate (XLD) agar 
Yeast extract  3.0 g 
Xylose   3.75 g 
Lactose   7.5 g 
Sucrose   7.5 g 
L-lysine Hcl   5.0 g 
Sodium Chloride  5.0 g 
Sodium deoxycholate 2.5 g 
Sodium thiosulphate 6.8 g 
Ferric ammonium citrate 0.8 g 
Phenol red   0.08 g 
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Agar    15 g 
Water    1 litre 
 All the ingredients except deoxycholate, thiosulphate and ferric 
ammonium citrate were dissolved in the water by autoclaving.  Cooled 
to 50°C and 20 ml of a solution of sodium thiosulphate 34% and ferric 
ammonium citrate 4% and 25ml of a solution of sodium deoxycholate 
10% were added, mixed.  pH adjusted to 6.9 and at once poured in 
plates.  Complete medium in powdered form is also available 
commercially. 
Mueller Hinton Agar 
Beef Infusion  - 300 ml 
Casein hydrolysate - 17.5 g 
Starch   - 1.5 g 
Agar    - 10 g 
Distilled water  - 1 litre 
 The starch was emulsified in a small amount of cold water and 
poured into the beef infusion and the casein hydrolysate and the agar 
were added.  The volume was made upto 1 litre with distilled water.  
The constituents were dissolved by heating gently at 100°C with 
agitation.  The pH was adjusted to 7.4.  Sterilized by autoclaving at 
121°C and poured in plates. 
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APPENDIX 6 
Media for Biochemical Identification of Bacteria 
Oxidase     Catalase 
Indole     Triple Sugar Iron agar 
Citrate     Urease 
Methyl red – Voges Proskauer  Nitrate reduction. 
Phenyl alanine deaminase test,  Carbohydrate Fermentation media 
1. Oxidase Reagent 
Tetra methyl P- phenylene diamine dihydro chloride -1% aqueous 
solution. 
2. Catalase Test 
3% Hydrogen peroxide 
3. Indole Reagent 
Kovac’s reagent 
Para dimethyl amino benzaldehyde -10gm 
Iso amyl alcohol -150ml 
Hydrochloric acid -80ml 
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4. Triple Sugar Iron Agar 
Sodium chloride 0.5gm 
Yeast extract 0.5gm 
Peptone 2gm 
Agar 1.5gm 
Distilled water 100ml 
Distilled by keeping in boiling water bath and the following 
ingredients were added. 
Lactose 1.0gm 
Sucrose 1.0gm 
Dextrose 0.1gm 
Sodium thio suiphate 0.03gm 
Ferrous suiphate 0.02gm 
pH adjusted to 7.6. Phenol red 0.0024gm (2.4 ml of 1% solution) 
was added and distributed into test tubes in 4ml quantities and 
autoclaved. The tubes were kept in a slanting position so that to get a 
deep but and a short slant. 
5. Simmon’s Citrate Agar 
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Sodium chloride 5.0g 
Magnesium sulphate 0.2g 
Ammonium dihydrogen phosphate 1.0g 
Potassium dihydrogen phosphate 1.0g 
Sodium citrate 5.0g 
Agar 20.0g 
Bromothymol blue (1/500 aqueous solution) 40ml 
Distilled water 100ml 
The ingredients were mixed and pH adjusted to 6.9 sterilized by 
autoclaving and poured into tubes as slopes. 
6. Christensen’s Urea Agar 
Urea solution 
Sodium chloride -5.0g 
Dextrose -1.0gm 
Trypticase -1.0gm 
Mono potassium phosphate -2.0gm 
Urea -20.0gm 
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Distilled water -100ml 
Phonol red 1% solution -1.2ml (in alcohol) 
Urea agar base 
Agar -1.5gm 
Distilled water -90ml 
 The ingredients were dissolved in distilled water. pH adjusted to 
6.8. Phenol red solution was added & sterilized by filtration. This is 
stock solution. 
 Agar was dissolved in distilled water and sterilized by autoclaving. 
Cooled to 45°C and 10ml of urea solution was added, dispensed in        
3-5ml quantities and allowed to form a small butt and long slant. 
7. Glucose Phosphate Broth (MR-VP medium) 
Dipotassium phosphate 5.0gm 
Glucose 5.0 gm 
Distilled water 100ml 
 The above ingredients were suspended in distilled water and 
heated slightly to dissolve them. Sterilized at 115° C for 15 minutes. 
8. Potassium Nitrate Broth 
Potassium nitrate (KNO3) 0.2gm 
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Peptone 5.0gm 
Distilled water 100ml 
 The above ingredients were mixed and transferred into tubes in 
5ml amount and autoclaved. 
9. Phenyl Alanine Deaminase Test 
Yeast extract    5g 
Disodium hydrogen phosphate  1g 
Agar      12g 
Di-Phenylalanine    2g 
Sodium chloride    5g 
Distilled water    1 litre 
pH adjusted to 7.4, distributed in tubes and sterilized by 
autoclaving at 121°C for 15 minutes, allowed to solidify as long slopes. 
APPENDIX 7 
Sabouraud Dextrose Agar (SDA) 
Peptone  1 gm 
Dextrose  4 gm 
Agar   2 gm 
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Chloramphenicol 5 mg 
Cycloheximide 50 mg 
Distilled water 100 ml 
All the ingredients were dissolved by boiling in a water bath.  
Cycloheximide was dissolved in 10 ml of acetone and added to the 
boiling medium.  Similarly, chloramphenicol was dissolved in 10 ml of 
95% alcohol and added to the boiling medium.  The medium was 
removed from heating, mixed well and then dispensed in tubes and 
autoclaved at 121°C for 15 minutes.  The pH adjusted to 5.4.  The tubes 
were cooled in slanted position and stored in the refrigerator. 
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ABBREVIATIONS 
 AFB  - Acid Fast Bacilli 
 ALL  - Acute Lymphatic Leukemia 
 AML  - Acute Myleoid Leukemia 
 ANC  - Absolute Neutrophil Count 
 BAP  - Blood Agar Plate 
 BHI  - Brain Heart Infusion 
 BSI  - Blood Stream Infection 
 CDI  - Clinically Documented Infection 
 CLL  - Chronic Lymphocytic Leukemia 
 CML  - Chronic Myleoid Leukemia 
 CONS - Coagulase negative staphylococcus  
 ESBL  - Extended Spectrum ß-Lactamase 
 FUO  - Fever of Unknown Origin 
 HBsAG - Hepatitis B Surface Antigen 
 HD  - Haematological Disorders 
 HIV  - Human Immunodeficiency Virus  
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 HL  - Hodgkin’s Lymphoma 
 LPCB  - Lactophenol Cotton Blue 
 MAC  - MacConkey Agar 
 NA  - Nutrient Agar 
 NHL  - Non-Hodgkin’s Lymphoma 
 NCCLS - National Committee for Clinical 
Laboratory Standards 
 SDA  - Sabouraud Dextrose Agar 
XLD  - Xylose Lysine Decarboxylase 
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